ANGO

ANGIO DYNAMICS, INC. (ANGO) — ANALYST NOTE Date: 2026-06-13 Event Date: 2026-06-13

1. Structural Readiness

As of the close on 2026-06-13, ANGO presents a confirmed coil setup. The breakout signal has fired, and the structure is currently actionable.

• Conservative Entry: $14.47
• Current Price: $13.82
• Extension: -4.5% vs. conservative entry.
• Setup Status: The setup is confirmed. While the current price sits below the conservative entry level, the "confirmed" designation indicates the breakout mechanism has already triggered in the historical record. The setup is not "forming" (which would imply a base in place but no breakout) nor is it "none." The presence of a confirmed coil is a partial positive readiness signal.
• Volatility Context: The ATR at the time of the breakout was 4.1% (High), indicating strong structural quality. The current ATR is 4.6% (High), reflecting elevated volatility suitable for position sizing but requiring careful capital allocation.

2. The Thesis Layer

At this date, ANGO is classified as a TACTICAL, setup-led name. There is no named secular thesis attached to this specific setup. The conviction must be derived entirely from the quality of the technical setup (the confirmed coil) and the immediate business fundamentals reported by management. We do not invent a macro thesis; we judge the name on the strength of the setup and the verifiable business data available as of 2026-06-13.

3. The Business

AngioDynamics, Inc. is a medical technology company focused on the development, manufacturing, and commercialization of devices for vascular access, peripheral vascular disease treatment, and oncology/surgical interventions. The company serves a specialized end-user base including interventional radiologists, cardiologists, vascular surgeons, urologists, and oncologists.

Key Business Metrics and Guidance (as of Q3 FY26 Earnings, 2026-04-02):

• Revenue Growth: For the three months ended February 28, 2026, net sales increased $6.4 million to $78.4 million compared to the prior year period.
• Guidance Raises: Management has raised full-year guidance for the third consecutive quarter.
• Net Sales: Now expected to be $313.5 million to $315.5 million (raised from $312M–$314M).
• Adjusted EBITDA: Now expected to be $10 million to $12 million (raised from $8M–$10M).
• Product Portfolio Performance:
• Auryon: Has delivered double-digit year-over-year growth for 19 consecutive quarters.
• Thrombus Management (AlphaVac/AngioVac): Combined portfolio grew approximately 18% year-over-year.
• NanoKnife: Total revenue was $7.6 million, an increase of 21%, with probe sales growing 20%.
• Med Tech Segment: Grew 19.0% in the third quarter of fiscal year 2026.
• Operational Efficiency: Total company gross margin increased by $2.6 million for the three months and $12.6 million for the nine months ended February 28, 2026.
• Backlog: As of February 28, 2026, the company reported a backlog of $0.3 million, consistent with their strategy to maintain sufficient inventory to ship within 24-48 hours.

4. Archetype and Conviction

Archetype: Quality Compounder (with elements of Margin Inflector).

• Fit: The company demonstrates a "Quality Compounder" profile through consistent revenue growth across multiple product lines (Auryon, NanoKnife, Thrombus Management) and a clear trajectory toward profitability, evidenced by the raised EBITDA guidance. The "Margin Inflector" aspect is supported by the $12.6 million increase in gross margin over nine months.
• Valuation Context: The financial spine indicates a forward consensus EPS of -0.1618 for FY1 and -0.1566 for FY2. While the company is currently reporting losses on a per-share basis, the raised EBITDA guidance suggests a path to profitability is being executed.
• Conviction Stack:
• Thesis Strength: Moderate (Tactical, no secular tailwind named).
• Evidence Quality: High (Multiple consecutive quarters of raised guidance, specific product growth data).
• Structural Quality: High (ATR at breakout 4.1% and current 4.6% fall within the "High" 4–6% sweet spot).
• Setup Readiness: Confirmed (Actionable coil).
• Rerating Potential: Dependent on the successful execution of the path to profitability and the continued double-digit growth of the Auryon and NanoKnife platforms.

5. Invalidations, Strengtheners, and Gaps

• What Would Strengthen: Continued execution of the raised guidance in the upcoming Q4 report (July 14, 2026). Specifically, if the company confirms that the "Med Tech" growth of 19% is sustained and the path to positive EPS is accelerated beyond the current consensus.
• What Would Invalidate: A failure to meet the raised full-year sales guidance ($313.5M–$315.5M) or a significant contraction in the Auryon or NanoKnife growth rates. A return to negative guidance revisions would contradict the "third consecutive quarter of raised guidance" narrative.
• Gaps in Evidence:
• Cash Flow: While EBITDA is raised, the specific free cash flow generation for the quarter is not detailed in the provided evidence, though the loss per share is noted.
• Long-Term Pipeline: While FDA IDE approval for NanoKnife BPH was noted in news (June 2026), the commercialization timeline and revenue impact of this specific new indication are not yet quantified in the financials.
• Macro Sensitivity: No specific data on how tariff or inflation pressures (mentioned in news) are impacting the gross margin expansion.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Third consecutive quarter of raised full-year guidance; Auryon double-digit growth for 19 consecutive quarters; Med Tech segment grew 19% in Q3 FY26; Confirmed coil setup with high ATR structural quality. Key risks: Forward consensus EPS remains negative for FY1 and FY2; Current price is -4.5% below conservative entry; Potential tariff and inflation pressures on margins; Small cap bucket volatility. Rating boundary: This is rated Buy rather than Strong Buy because the current price is below the conservative entry level, creating a slight execution risk on the immediate setup, and the company is still in a pre-profitability phase (negative EPS consensus). It is rated Buy rather than Speculative because the business fundamentals show a clear, multi-quarter trend of raised guidance and double-digit growth across core products, providing a stronger fundamental floor than a typical speculative setup. Sizing hint: Position size should reflect the high ATR (4.6%) and the fact that the price is currently trailing the entry, suggesting a need for tighter risk management on the initial tranche. Expected path: Management expects to continue raising guidance if execution holds; the market will likely re-rate the stock as the Q4 earnings report (July 14) confirms the ability to meet the raised $313.5M–$315.5M sales target and the path to EBITDA profitability. Expected horizon: 3 to 6 months, aligned with the release of Q4 results and the confirmation of full-year guidance achievement. Failure mode to watch: A miss on the raised full-year sales guidance or a reversal of the EBITDA guidance in the upcoming Q4 earnings call.